End-of-day quote
Shanghai S.E.
06:00:00 2024-05-26 pm EDT
|
5-day change
|
1st Jan Change
|
59.9
CNY
|
+0.37%
|
|
-5.51%
|
-10.50%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
40,032
|
70,286
|
74,544
|
65,081
|
32,239
|
28,565
|
-
|
-
|
Enterprise Value (EV)
1 |
40,032
|
70,286
|
72,968
|
63,812
|
31,225
|
27,294
|
27,080
|
26,703
|
P/E ratio
|
68.4
x
|
108
x
|
95.9
x
|
67.3
x
|
54.4
x
|
34
x
|
25.6
x
|
22.9
x
|
Yield
|
0.44%
|
0.28%
|
0.32%
|
0.45%
|
0.57%
|
0.87%
|
1.13%
|
1.22%
|
Capitalization / Revenue
|
21.2
x
|
26.7
x
|
15.1
x
|
10.2
x
|
5.31
x
|
4.18
x
|
3.47
x
|
3.13
x
|
EV / Revenue
|
21.2
x
|
26.7
x
|
14.7
x
|
10
x
|
5.14
x
|
3.99
x
|
3.29
x
|
2.93
x
|
EV / EBITDA
|
53.1
x
|
84.5
x
|
70.6
x
|
48.6
x
|
33.2
x
|
22.1
x
|
17.8
x
|
15
x
|
EV / FCF
|
-
|
-
|
148
x
|
-1,064
x
|
-94.4
x
|
-39.7
x
|
23.5
x
|
24.1
x
|
FCF Yield
|
-
|
-
|
0.67%
|
-0.09%
|
-1.06%
|
-2.52%
|
4.25%
|
4.14%
|
Price to Book
|
8.8
x
|
14
x
|
13.1
x
|
9.81
x
|
4.64
x
|
3.8
x
|
3.38
x
|
3.09
x
|
Nbr of stocks (in thousands)
|
480,000
|
480,000
|
480,000
|
481,085
|
481,678
|
478,638
|
-
|
-
|
Reference price
2 |
83.40
|
146.4
|
155.3
|
135.3
|
66.93
|
59.68
|
59.68
|
59.68
|
Announcement Date
|
2/28/20
|
2/25/21
|
2/25/22
|
2/27/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,886
|
2,633
|
4,948
|
6,359
|
6,076
|
6,839
|
8,230
|
9,115
|
EBITDA
1 |
753.7
|
832.1
|
1,033
|
1,314
|
941.4
|
1,238
|
1,523
|
1,777
|
EBIT
1 |
699.6
|
757
|
905.6
|
1,136
|
708.4
|
980.7
|
1,295
|
1,455
|
Operating Margin
|
37.1%
|
28.76%
|
18.3%
|
17.87%
|
11.66%
|
14.34%
|
15.74%
|
15.96%
|
Earnings before Tax (EBT)
1 |
584.6
|
758.9
|
890.2
|
1,136
|
701.7
|
1,000
|
1,349
|
1,492
|
Net income
1 |
585.6
|
645.8
|
782.3
|
970.9
|
592.6
|
844.9
|
1,125
|
1,258
|
Net margin
|
31.06%
|
24.53%
|
15.81%
|
15.27%
|
9.75%
|
12.36%
|
13.67%
|
13.8%
|
EPS
2 |
1.220
|
1.350
|
1.620
|
2.010
|
1.230
|
1.755
|
2.336
|
2.611
|
Free Cash Flow
1 |
-
|
-
|
491.9
|
-59.98
|
-330.7
|
-687
|
1,152
|
1,106
|
FCF margin
|
-
|
-
|
9.94%
|
-0.94%
|
-5.44%
|
-10.05%
|
14%
|
12.13%
|
FCF Conversion (EBITDA)
|
-
|
-
|
47.62%
|
-
|
-
|
-
|
75.63%
|
62.26%
|
FCF Conversion (Net income)
|
-
|
-
|
62.87%
|
-
|
-
|
-
|
102.37%
|
87.93%
|
Dividend per Share
2 |
0.3700
|
0.4100
|
0.4900
|
0.6100
|
0.3800
|
0.5165
|
0.6748
|
0.7269
|
Announcement Date
|
2/28/20
|
2/25/21
|
2/25/22
|
2/27/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1,937
|
1,936
|
-
|
1,681
|
1,385
|
2,039
|
3,424
|
1,305
|
1,770
|
3,076
|
1,146
|
1,854
|
1,889
|
1,379
|
2,145
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
574
|
124.9
|
126.3
|
-
|
-
|
EBIT
1 |
-
|
258.2
|
-
|
338.1
|
242.5
|
313.8
|
556.3
|
243.1
|
274.5
|
-
|
93.55
|
-
|
292.6
|
141.8
|
173.1
|
-
|
-
|
Operating Margin
|
-
|
13.34%
|
-
|
20.12%
|
17.51%
|
15.39%
|
16.25%
|
18.63%
|
15.5%
|
-
|
8.16%
|
-
|
15.49%
|
10.29%
|
8.07%
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
360.6
|
227
|
-
|
-
|
-
|
293.5
|
497.7
|
-
|
224.1
|
424.6
|
89.79
|
78.16
|
336.5
|
143.6
|
172.5
|
-
|
-
|
Net margin
|
18.62%
|
11.73%
|
-
|
-
|
-
|
14.39%
|
14.54%
|
-
|
12.66%
|
13.81%
|
7.84%
|
4.21%
|
17.81%
|
10.42%
|
8.04%
|
-
|
-
|
EPS
2 |
-
|
0.4700
|
-
|
0.5600
|
0.4300
|
0.6000
|
-
|
0.4200
|
0.4600
|
-
|
0.1900
|
0.1600
|
0.5805
|
0.3346
|
0.4146
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.5661
|
-
|
-
|
-
|
0.6640
|
Announcement Date
|
8/30/21
|
2/25/22
|
4/25/22
|
7/20/22
|
10/28/22
|
2/27/23
|
2/27/23
|
4/28/23
|
8/29/23
|
8/29/23
|
10/30/23
|
2/29/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
1,576
|
1,269
|
1,013
|
1,271
|
1,485
|
1,862
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
492
|
-60
|
-331
|
-687
|
1,152
|
1,106
|
ROE (net income / shareholders' equity)
|
18.7%
|
13.5%
|
14.6%
|
15.8%
|
8.31%
|
11.3%
|
13.3%
|
13.6%
|
ROA (Net income/ Total Assets)
|
16.6%
|
12.1%
|
11.8%
|
12%
|
6.86%
|
9.08%
|
10.7%
|
11.3%
|
Assets
1 |
3,521
|
5,344
|
6,610
|
8,093
|
8,643
|
9,307
|
10,507
|
11,096
|
Book Value Per Share
2 |
9.480
|
10.50
|
11.90
|
13.80
|
14.40
|
15.70
|
17.60
|
19.30
|
Cash Flow per Share
2 |
0.7600
|
1.470
|
2.640
|
1.320
|
1.450
|
2.360
|
2.940
|
3.290
|
Capex
1 |
450
|
763
|
784
|
695
|
1,030
|
591
|
452
|
484
|
Capex / Sales
|
23.88%
|
28.97%
|
15.85%
|
10.93%
|
16.96%
|
8.64%
|
5.49%
|
5.31%
|
Announcement Date
|
2/28/20
|
2/25/21
|
2/25/22
|
2/27/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
59.68
CNY Average target price
72.07
CNY Spread / Average Target +20.76% Consensus |
1st Jan change
|
Capi.
|
---|
| -10.83% | 3.94B | | -2.00% | 90.02B | | -1.18% | 39.15B | | -15.83% | 31.71B | | +62.86% | 26.47B | | -21.68% | 14.34B | | -8.73% | 12.89B | | -15.05% | 11.18B | | -45.69% | 10.97B | | +4.94% | 8.94B |
Biopharmaceuticals
|